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Abstract
Background: Obesity is a significant global health problem, with approximately 50% of women entering pregnancy
having a body mass index greater than or equal to 25 kg/m2. Obesity during pregnancy is associated with a
well-recognised increased risk of adverse health outcomes both for the woman and her infant. Currently available
data from large scale randomised trials and systematic reviews highlight only modest effects of antenatal dietary
and lifestyle interventions in limiting gestational weight gain, with little impact on clinically relevant pregnancy
outcomes. Further information evaluating alternative strategies is required.
The aims of this randomised controlled trial are to assess whether the use of metformin as an adjunct therapy to
dietary and lifestyle advice for overweight and obese women during pregnancy is effective in improving maternal,
fetal and infant health outcomes.
Methods: Design: Multicentre randomised, controlled trial.
Inclusion Criteria: Women with a singleton, live gestation between 10+0-20+0 weeks who are obese or overweight
(defined as body mass index greater than or equal to 25 kg/m2), at the first antenatal visit.
Trial Entry & Randomisation: Eligible, consenting women will be randomised between 10+0 and 20+0 weeks
gestation using an online computer randomisation system, and randomisation schedule prepared by non-clinical
research staff with balanced variable blocks. Stratification will be according to maternal BMI at trial entry, parity, and
centre where planned to give birth.
Treatment Schedules: Women randomised to the Metformin Group will receive a supply of 500 mg oral metformin
tablets. Women randomised to the Placebo Group will receive a supply of identical appearing and tasting placebo
tablets. Women will be instructed to commence taking one tablet daily for a period of one week, increasing to a
maximum of two tablets twice daily over four weeks and then continuing until birth. Women, clinicians, researchers
and outcome assessors will be blinded to the allocated treatment group.
All women will receive three face-to-face sessions (two with a research dietitian and one with a trained research assistant),
and three telephone calls over the course of their pregnancy, in which they will be provided with dietary and lifestyle
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advice, and encouraged to make change utilising a SMART goals approach.
Primary Study Outcome: infant birth weight >4000 grams.
Sample Size: 524 women to detect a difference from 15.5% to 7.35% reduction in infants with birth weight >4000 grams
(p = 0.05, 80% power, two-tailed).
Discussion: This is a protocol for a randomised trial. The findings will contribute to the development of evidence based
clinical practice guidelines.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12612001277831, prospectively registered
10th of December, 2012.
Background
Overweight and obesity represents a significant global
health issue, affecting approximately 2.1 billion adults
world-wide, [1] with approximately 50% of women enter-
ing pregnancy with a body mass index (BMI) in excess of
25 kg/m2 [2]. The risks associated with obesity during
pregnancy and childbirth have been well-documented,
and increase with advancing BMI [3]. Immediate preg-
nancy and birth complications include hypertension and
pre-eclampsia, gestational diabetes, need for induction of
labour, caesarean section and perinatal death, [3, 4] while
infants born to women who are obese are more likely to
be macrosomic, require admission to the neonatal inten-
sive care unit, be born preterm, have a congenital anom-
aly, and require treatment for jaundice or hypoglycaemia
[3, 4]. Increasingly, there is recognition of a longer-term
health legacy, maternal obesity being associated with a
greatly increased risk of both diabetes [5] and cardiovas-
cular disease for the woman, [6] and a significant pre-
dictor of obesity in her offspring [7–9].
There is a substantial literature on gestational weight
gain during pregnancy summarised by the Institute of
Medicine [10]. While these recommendations advocate
gestational weight gain of 7–11.5 kg for women who are
overweight, and 5-9 kg for women who are obese, [10] a
systematic review [11] and large-scale randomised trials
[12, 13] highlight only modest effects of antenatal dietary
and lifestyle interventions in limiting gestational weight
gain, with little impact on clinically relevant pregnancy
outcomes [11–13]. Alternative strategies during preg-
nancy to improve health outcomes for women who are
overweight or obese, and their infants, are required.
Increasing maternal BMI is a well-recognised risk
factor for the development of gestational diabetes, [3, 4]
with the two conditions creating a similar metabolic
environment, characterised by insulin resistance, hyper-
glycaemia, hyperlipidaemia, and a low-grade state of
chronic inflammation, all of which influence nutrient
availability for fetal growth [14]. Furthermore, women
who enter pregnancy overweight or obese have an
increased state of insulin resistance when compared with
women of normal BMI [15, 16].
Metformin is an oral biguanide, has insulin sensitising
properties, and is used increasingly in the treatment of
gestational diabetes [17]. Metformin inhibits both
gluconeogenesis and glycogenolysis, thereby reducing
hepatic glucose production, [18] while increasing insulin
mediated skeletal muscle and adipocyte glucose utilisa-
tion [19]. Metformin also promotes weight loss in non-
pregnant individuals [20, 21].
Given the limited effect of antenatal dietary and life-
style interventions during pregnancy on both gestational
weight gain and clinical pregnancy and birth outcomes,
[11–13] there is a need for further evaluation of the role
of adjuvant therapies, including metformin, as a strategy
to improve health for women who are overweight or
obese. The aims of this randomised trial are to evaluate
the effects of antenatal metformin and dietary advice
among overweight and obese pregnant women on ma-
ternal, fetal and infant health outcomes.
The primary hypothesis is that antenatal metformin
and dietary advice in overweight and obese pregnant
women will reduce the risk of an infant with birth
weight greater than 4000 grams.
The secondary hypotheses are that antenatal meltfor-
min and dietary and lifestyle advice in overweight and
obese pregnant women will
 Reduce the risk of morbidity from other adverse
outcomes for the infant;
 Reduce the risk of maternal morbidity from adverse
outcomes;
 Improve maternal quality of life and well-being; and
 Reduce the costs of health care.
Methods
Study design
Multicentre randomised, placebo controlled trial.
Study setting
Public maternity hospitals in metropolitan Adelaide in-
cluding the Women’s and Children’s Hospital, The Lyell
McEwin Hospital and Flinders Medical Centre.
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Inclusion criteria
Women with a singleton, live gestation between 10+0-20+0
weeks who are overweight (BMI 25.0 to 29.9 kg/m2) or
obese (BMI ≥30 kg/m2), at their first antenatal visit will be
eligible to participate.
Exclusion criteria
Women with a multiple pregnancy, type 1 or 2 diabetes
diagnosed prior to pregnancy, or with significant renal
or hepatic impairment such that metformin would be
contraindicated will be excluded from participation.
Trial entry
Eligible women will be identified in the antenatal clinic of
participating centres, given the trial information sheet and
counselled by a researcher, before obtaining informed
written consent. Randomisation will occur using the
computer based randomisation service of the Discipline of
Obstetrics and Gynaecology, The University of Adelaide.
The randomisation schedule will use balanced variable
blocks, and will be prepared by an investigator not involved
with recruitment or clinical care. There will be stratification
of women according to parity (0 versus 1 or more), BMI at
booking visit (25 to 29.9 kg/m2 versus ≥30 kg/m2), and
collaborating centre. Eligible women will be randomised to
either the ‘Metformin Group’ or the ‘Placebo Group’.
Supply and blinding of study medication
Metformin tablets 500 mg and placebo tablets identical in
appearance will be packed by an independent pharmaceut-
ical packaging company (Pharmaceutical Packaging Profes-
sionals, Victoria) and coded according to the randomisation
schedule. The women, their caregivers and research staff
will be blinded to treatment allocation. Research staff
obtaining outcome data will be blinded to treatment alloca-
tion. In the unexpected situation where a clinician directly
involved in the care of an individual woman considers it
essential to ongoing clinical care that treatment group
allocation be revealed, this will be performed by an individ-
ual not directly involved in the day-to-day management of
the trial, and conveyed directly to the clinician.
Treatment schedules
Women who are randomised to the Metformin Group will
receive a 16 week supply of oral metformin tablets 500 mg,
and a further 12 week supply at 28 weeks of their pregnancy.
Women will be instructed to commence taking tablets from
the time of randomisation, starting with one tablet daily for
a period of one week, increasing to a maximum of two
tablets twice daily (maximum dose 2000 mg daily) over four
weeks as tolerated and then continuing until birth.
Women who are randomised to the Placebo Group will
receive a 16 week supply of identical appearing placebo
tablets, and a further 12 week supply at 28 weeks of their
pregnancy. Women will instructed to commence taking
tablets from the time of randomisation, starting with one
tablet daily for a period of one week, increasing to a max-
imum of two tablets twice daily over four weeks as toler-
ated and then continuing until birth.
Treatment compliance will be assessed via completion of
a short questionnaire at 36 weeks’ gestation in which women
will be asked whether they have taken the medication during
the previous month. Women who respond ‘no’ will be con-
sidered non-compliant with the treatment, and will be asked
to indicate why they are not taking the study medication.
All women will be asked if they have experienced symptoms
consistent with known side effects of metformin.
Ongoing follow-up of all women in both treatment
groups
Over the course of pregnancy, each woman will receive three
face-to-face sessions (two with the dietitian shortly after trial
entry and again at 28 weeks gestation, and one with a re-
search assistant at 36 weeks gestation) and three telephone
calls from the research assistant at 20, 24, and 32 weeks
gestation. The intervention has been designed to maximise
flexibility and choice for women, while providing advice that
can be incorporated into each individual’s lifestyle.
Dietary advice provided will be consistent with current
Australian dietary standards, [22] and based on our ex-
perience with the LIMIT randomised trial [12, 23]. The
dietary intervention will maintain a balance of carbohy-
drates, fat and protein, while specifically encouraging
women to reduce their intake of energy dense and non-
core foods high in refined carbohydrates and saturated
fats, while increasing their intake of fibre, and promoting
consumption of two serves of fruit, five serves of vegeta-
bles, and three serves of dairy each day [12, 22, 23].
Tailoring of the intervention will be informed by stage
theories of health decision making that propose that indi-
viduals progress through a series of cognitive phases when
undertaking behavioural change [24]. Initially, there will be
a planning session with a research dietitian, in which
women will be provided with written dietary and activity
information, an individual diet and physical activity plan,
recipe book and example menu plans. Women will be en-
couraged to set achievable goals for dietary and exercise
change, supported to make these lifestyle changes and to
self-monitor their progress, using a SMARTgoals approach.
Women will be encouraged to involve their partner or sig-
nificant support person in these sessions. These principles
will be reinforced at subsequent face-to-face visits with the
dietitian and research assistant, and during the telephone
contacts [12, 23].
All women will be asked to complete a food frequency
questionnaire, exercise diary, and quality of life assess-
ments at trial entry, 28 and 36 weeks gestation, and six
months postpartum. Their weight will be recorded at trial
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entry, at 28 weeks gestation, and at 36 weeks gestation or
nearest to birth. All women will be encouraged to attend
for a research ultrasound at 28 and 36 weeks gestation
that does not constitute routine clinical care, to monitor
fetal growth, and in particular the development of small
for gestational age infants.
For women who are diagnosed with gestational diabetes,
it will be assumed that they are receiving metformin, and
further metformin or insulin will be added as required to
maintain appropriate glycaemic control as determined by
her health care provider. All other care during pregnancy
and birth will be according to the practices of the hospital
at which the woman is booked to give birth.
After birth, information will be obtained relating to
birth and infant outcomes from the case notes by the re-
search assistant and the delivery form completed. Simi-
larly, the postnatal and neonatal forms will be completed
for each live born infant after discharge from hospital.
See Table 1 for an outline of timing enrolment, inter-
vention and assessments.
Study endpoints
The primary trial outcome is the incidence of infants
with birth weight >4000 grams.
The secondary study outcomes are:
1) Adverse outcomes for the infant including preterm
birth (birth before 37 weeks gestation); mortality (either
stillbirth (intrauterine fetal death after trial entry and
prior to birth), or infant death (death of a live born
infant prior to hospital discharge, and excluding lethal
congenital anomalies)); infant birth weight <2500 grams;
infant birth weight >4500 grams; infant birth weight
>90th centile for gestational age and infant sex; infant
birth weight <10th centile for gestational age and infant
sex; hypoglycaemia requiring intravenous treatment;
admission to neonatal intensive care unit, or special care
baby unit; hyperbilirubinaemia requiring phototherapy;
nerve palsy; fracture; birth trauma; shoulder dystocia.
2) Maternal weight gain outcomes including total
gestational weight gain and gestational weight gain
classified as below/within/above IoM
recommendations [10].
3) Maternal changes in diet and physical activity as
measured by questionnaires completed by the
woman at trial entry, 28 and 36 weeks gestation,
and six and 18 months after birth (Harvard Semi-
quantitative Food Frequency Questionnaire,
[25, 26] and the Short Questionnaire to Assess
Health-enhancing physical activity (SQUASH) [27]).
4) Adverse outcomes for the woman including maternal
hypertension and pre-eclampsia (in accordance with
recognised Australasian Society for the Study of
Hypertension in Pregnancy criteria) [28]; maternal
gestational diabetes [29]; need for and length of
antenatal hospital stay; antepartum haemorrhage
requiring hospitalisation; preterm prelabour ruptured
membranes; chorioamnionitis; need and reason for
induction of labour; any antibiotic use during labour;
caesarean section; postpartum haemorrhage (blood
loss ≥600 mL); perineal trauma; wound infection;
endometritis; length of postnatal hospital stay;
thromboembolic disease; maternal death.
5) Maternal quality of life and emotional wellbeing as
measured by questionnaires completed by the woman
at trial entry, 28 and 36 weeks of pregnancy and six
months postpartum relating to quality of life (as
measured using the SF12 Health Survey Questionnaire);
[30] preferences for treatment and satisfaction with
care (at 6 months postpartum only); anxiety (as
measured by the Short Form Spielberger State Trait
Inventory [31]) and depression (as measured by the
Edinburgh Postnatal Depression Scale [32]).Women
will be asked a series of questions about their
satisfaction with the intervention, using items modified
from a previous childbirth questionnaire [33].
6) Fetal growth and wellbeing at 28 and 36 weeks’
gestation assessed by ultrasound (fetal biometry,
estimated weight, liquor volume, umbilical artery
Doppler waveform, and adiposity) [34].
7) Costs of health care: The primary measure of outcome
for the economic analysis will be the cost per live birth.
Resource use will include the provision of the dietary
intervention and direct costs of health care (expected
average clinic fees, the frequency and duration of GP
and antenatal visits, as well as in-patient admissions),
determined by hospital out-patient visits, in-patient
admissions and published data sets including PBS, MBS
and Australian Refined Diagnosis Related Groups
(AR-DRG) cost weights. Mean costs and effectiveness
between treatment groups will be compared and
incremental cost effectiveness ratios (ICERs) and
confidence intervals presented. For varying threshold
values of cost effectiveness, acceptability curves will be
presented as described previously [35]. An assessment
of the sensitivity of the results to variation in measured
resource use, effectiveness and/or unit costs will be
undertaken using appropriate one-way and multi-way
sensitivity analysis, as described previously [35].
Women will be asked to provide consent to the collec-
tion of bio-specimens (including blood/serum at trial
entry, 28 weeks gestation and 36 weeks gestation, and
cord blood) for potential use in future ancillary studies.
Sample size
The primary clinical endpoint is the incidence of infants
born with birth weight >4000 grams, with an estimated
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Table 1 Timeline of main activities from recruitment to the end of the clinical trial
Eligibility
screen
Informed
consent
Allocation Commence study
medication
Dietary review Weight Questionnaires Fetal ultrasound Glucose
tolerance
test (GTT)
Baby
measurements
Pregnancy and
birth outcomes
Pre-randomisation ✓ ✓ ✓
Randomisation ✓
During
Pregnancy
As soon as practicable
after randomisation
✓ ✓ ✓
28 weeks ✓ ✓ ✓ ✓
36 weeks ✓ ✓ ✓ ✓
As soon as practicable
after birth
✓
Six weeks after birth ✓
D
odd
et
al.BM
C
Pregnancy
and
Childbirth
 (2016) 16:359 
Page
5
of
7
incidence in women eligible for this trial of 15.5% [12].
To detect a difference from 15.5% to 7.35% (alpha 0.05;
power 80%), and accounting for 5% rate of attrition
(based on our experience with the LIMIT Study), [12]
we will recruit a total of 524 women. This sample size
will be powered (80%) to detect the differences in sec-
ondary outcomes as detailed in the table below.
Data management
All information obtained from this study will remain
strictly confidential. While the results of the study will
be published, no data will be presented to allow the
identification of individual women. Data will be stored
in a locked filing cabinet or on password protected com-
puter file, and accessible only by the study team.
We have previous experience recruiting women for life-
style intervention trials in this setting [12] and will consider
adding further sites as required. Women who withdraw
from ongoing participation after randomisation will be
asked for consent to utilise the data already collected prior
to withdrawal, including birth outcomes where possible.
Analysis and reporting of results
The initial analysis will examine baseline characteristics of all
randomised women, as an indication of comparable treat-
ment groups, and include maternal age, parity, race, height,
weight, smoking history, past obstetric history, and previous
gestational diabetes. Primary and secondary outcomes will
be analysed on an “intention to treat” basis, according to
treatment allocation at randomisation; multiple imputation
by the fully conditional specification (chained equations)
method will be used to impute missing outcome data relative
risks and 95% confidence intervals will be reported for the
major outcomes, and the number needed to treat to benefit
or harm calculated. Analyses will be adjusted for stratifica-
tion variables, and for prespecified prognostic factors identi-
fied as potential confounders for particular outcomes. More
specific details relating to the proposed analyses, including
the handling of missing data will be outlined in the statistical
analysis plan to be developed for the trial.
As the lead investigator, JMD will have access to the
data, and acts as guarantor to the final data set. The trial
manager (ARD) and statistician (JL) will have access to
the data, and the statistician (JL) will be responsible for
the development of the statistical analysis plan, prior to
the conduct of any statistical analyses.
Following completion of the relevant statistical ana-
lyses, manuscripts will be prepared for publication, with
subsequent presentation of results at relevant scientific
and clinical meetings.
Ethics approval
Approval to conduct this study has been obtained from
the Women's and Children's Health Network (WCHN)
Human Research Ethics Committee's (HREC) and local
institutional approval at Women’s and Children’s Hospital,
Flinders Medical Centre and the Lyell McEwin Hospital.
Any amendments to the trial protocol will be notified in
writing to each of the responsible HREC’s, research assis-
tants, and clinicians involved in the study, and where rele-
vant an amendment made to the trial registration.
A data and safety monitoring board (DSMB) will monitor
efficacy (or futility) and adverse effects. Based on these con-
siderations, the DSMB may recommend that the protocol
be modified or that the GRoW trial be terminated. The
DSMB will consist of experts in relevant obstetrics, neonat-
ology and research methodology. All adverse events involv-
ing women and infants enrolled in the trial will be reviewed
by a multidisciplinary committee, who will be blinded to
treatment allocation, in order to clarify cause. These data
will be made available for the Data Safety Monitoring Board.
Discussion
This is a protocol for a randomised trial assessing whether
the use of metformin in pregnancy, as an adjuvant therapy
to dietary and lifestyle advice for women who are over-
weight or obese is effective in improving maternal, fetal
and infant health outcomes. The findings of this trial will
contribute to the currently available literature regarding
the effect of metformin in pregnancy for women who are
overweight and obese, [36, 37] and to the development of
evidence based clinical practice guidelines.
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